The global hyoscine market size was estimated to be USD 422.3 million in 2023 and is expected to reach USD 715.4 million by 2034 with a CAGR of 4.91% during the forecast period 2024-2034. Increasing demand for pharmaceuticals, growing awareness and prevalence of motion sickness, expanding applications in the treatment of gastrointestinal disorders, rising incidence of nausea and vomiting, advancements in drug delivery systems, and growing preference for non-invasive treatments will drive the market growth.
In the pharmaceutical business, hyoscine, sometimes referred to as scopolamine, is used to treat several illnesses, such as motion sickness, nausea, and vomiting. The market is expanding due in part to the need for drugs that include hyoscine. For instance, in November 2023, Johnson & Johnson partnered with Alnylam Pharmaceuticals to research and market RNAi therapies for gastrointestinal illnesses.
By type, the hyoscine butyl bromide segment accounted for the highest revenue-grossing segment in the global hyoscine market in 2023 owing to the compound's widespread use in pharmaceuticals for its effectiveness in alleviating gastrointestinal disorders, including irritable bowel syndrome, and its growing adoption in medical settings for its role in addressing conditions such as postoperative nausea and vomiting, thereby fueling increased demand and market dominance. For instance, in December 2023, GlaxoSmithKline plc announced that a novel combination medication for irritable bowel syndrome (IBS) based on hyoscine will be tested in a Phase III clinical study. Additionally, the hyoscine hydrobromide segment is predicted to grow at the fastest CAGR during the forecast period owing to the compound's enhanced bioavailability, increased efficacy, and expanded applications in the treatment of various medical conditions, such as motion sickness, nausea, and vomiting.
By mode of administration, the oral segment accounted for the highest revenue-grossing segment in the global hyoscine market in 2023 owing to the convenience and patient-friendly administration of oral formulations, which have gained widespread acceptance. For instance, in August 2023, the FDA approved a transdermal hyoscine patch made by Boehringer Ingelheim International GmbH to treat motion sickness. Additionally, the patches segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for convenient and non-invasive drug delivery systems.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global hyoscine market in 2023 owing to the widespread accessibility of hyoscine-based medications for consumers through established retail pharmacy networks. For instance, in July 2023, Pfizer Inc. invested in a startup company creating a revolutionary oral delivery method for hyoscine. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of digital platforms for purchasing pharmaceuticals, including hyoscine-based medications.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust healthcare infrastructure, high healthcare expenditure, and a significant prevalence of conditions such as motion sickness and gastrointestinal disorders. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the expanding healthcare infrastructure, rising disposable income, and increasing awareness about healthcare solutions. For instance, in October 2023, Sanofi initiated a public awareness campaign in Europe about the appropriate and secure use of hyoscine for motion sickness.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
In the pharmaceutical business, hyoscine, sometimes referred to as scopolamine, is used to treat several illnesses, such as motion sickness, nausea, and vomiting. The market is expanding due in part to the need for drugs that include hyoscine. For instance, in November 2023, Johnson & Johnson partnered with Alnylam Pharmaceuticals to research and market RNAi therapies for gastrointestinal illnesses.
By type, the hyoscine butyl bromide segment accounted for the highest revenue-grossing segment in the global hyoscine market in 2023 owing to the compound's widespread use in pharmaceuticals for its effectiveness in alleviating gastrointestinal disorders, including irritable bowel syndrome, and its growing adoption in medical settings for its role in addressing conditions such as postoperative nausea and vomiting, thereby fueling increased demand and market dominance. For instance, in December 2023, GlaxoSmithKline plc announced that a novel combination medication for irritable bowel syndrome (IBS) based on hyoscine will be tested in a Phase III clinical study. Additionally, the hyoscine hydrobromide segment is predicted to grow at the fastest CAGR during the forecast period owing to the compound's enhanced bioavailability, increased efficacy, and expanded applications in the treatment of various medical conditions, such as motion sickness, nausea, and vomiting.
By mode of administration, the oral segment accounted for the highest revenue-grossing segment in the global hyoscine market in 2023 owing to the convenience and patient-friendly administration of oral formulations, which have gained widespread acceptance. For instance, in August 2023, the FDA approved a transdermal hyoscine patch made by Boehringer Ingelheim International GmbH to treat motion sickness. Additionally, the patches segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for convenient and non-invasive drug delivery systems.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global hyoscine market in 2023 owing to the widespread accessibility of hyoscine-based medications for consumers through established retail pharmacy networks. For instance, in July 2023, Pfizer Inc. invested in a startup company creating a revolutionary oral delivery method for hyoscine. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of digital platforms for purchasing pharmaceuticals, including hyoscine-based medications.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust healthcare infrastructure, high healthcare expenditure, and a significant prevalence of conditions such as motion sickness and gastrointestinal disorders. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the expanding healthcare infrastructure, rising disposable income, and increasing awareness about healthcare solutions. For instance, in October 2023, Sanofi initiated a public awareness campaign in Europe about the appropriate and secure use of hyoscine for motion sickness.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Mode of Administration, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Hyoscine Market Report 2023 - 2034
Hyoscine Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Mn)
- Hyoscine Butyl Bromide
- Hyoscine Hydrobromide
Hyoscine Market Analysis & Forecast by Mode of Administration 2023 - 2034 (Revenue USD Mn)
- Oral
- Patches
- Injections
Hyoscine Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Mn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Hyoscine Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Hyoscine Market: Type Estimates & Trend Analysis
8. Hyoscine Market: Mode of Administration Estimates & Trend Analysis
9. Hyoscine Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Hyoscine Market
12. Europe Global Hyoscine Market
13. Asia Pacific Global Hyoscine Market
14. Latin America Global Hyoscine Market
15. MEA Global Hyoscine Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Johnson & Johnson
- GlaxoSmithKline plc
- Boehringer Ingelheim International GmbH
- Novartis International AG
- Pfizer Inc.
- Sanofi
- Baxter International Inc.
- Takeda Pharmaceutical Company Limited
- Fresenius SE & Co. KGaA
- Abbott Laboratories
- Perrigo Company plc
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Wockhardt Ltd.
- Ipca Laboratories Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 422.3 Million |
| Forecasted Market Value ( USD | $ 715.4 Million |
| Compound Annual Growth Rate | 4.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
